Stuttering Market

DelveInsight’s ‘Stuttering-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the stuttering, historical and forecasted epidemiology as well as the stuttering market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. 

 

The stuttering market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM stuttering market size from 2019 to 2032. The Report also covers current stuttering treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Stuttering Disease Understanding and Treatment Algorithm

Stuttering Overview

Childhood-onset fluency disorder, also known as stuttering or stammering, is a common multifactorial speech disorder. It is a disruption in the fluency of verbal expression characterized by involuntary, audible, or silent repetitions or prolongations of sounds or syllables. These are not readily controllable and may be accompanied by other movements and by emotions of negative nature such as fear, embarrassment, or irritation, and are normally seen with recurrent prolongations, reverberations, or blocks of sounds, syllables, phrases, or words.

 

As it is a disorder in the fluency of speech, in addition to involuntary repetition and prolongation of sounds and syllables, there is also “secondary stuttering behavior,” which occurs as a response to the core stuttering behavior. These can be further explained by the example of “flight behaviors”, varying from choosing synonyms for the feared words to opting for social isolation to avoid speaking and concealing the stuttering out of anxiety, frustration, and shame. There are also “fight behaviors” varying from unnatural eye-blinking to involuntary movement of the extremities.

 

Stuttering arises, in general, before age 6, usually between 2.5 and 4 years of age. The most common form of stuttering is referred to as developmental stuttering. This may be contrasted with other forms of stuttering, which, for instance, arise from a neurological condition, trauma or emotional stress. Clinical diagnosis typically measures the rates of stuttering disfluencies while reading or during free speech and can include the rate of ancillary symptoms, sometimes known as struggle behaviors, during speech. The disorder resolves in most individuals, either spontaneously or with the help of speech therapy; however, approximately 20–25% of cases do not resolve, leading to a condition known as persistent developmental stuttering, which affects about 1% of the general population. 

 

Stuttering Diagnosis 

Stuttering is usually diagnosed by a speech-language pathologist (SLP), a health professional trained to test and treat individuals with voice, speech, and language disorders. The SLP will consider a variety of factors, including the following:

  • Child’s case history (such as when the stuttering was first noticed and under what circumstances)
  • An analysis of the child’s stuttering behaviors
  • An evaluation of the child’s speech and language abilities and the impact of stuttering on their life

 

When evaluating a young child for stuttering, a speech-language pathologist will try to determine if the child is likely to continue their stuttering behavior or outgrow it. To determine this difference, the SLP will consider such factors as the family’s history of stuttering, whether the child’s stuttering has lasted six months or longer, and whether the child exhibits other speech or language problems.

 

Some aspects of stuttering are apparent, while others are not. A speech-language pathologist (SLP) can make a comprehensive and reliable diagnosis. Stuttering is more than disfluencies, so it is important to see an SLP for testing.

 

Different guidelines and expert committees have designated different parameters for classification of stuttering.

Continued in the report…..

 

Stuttering Treatment 

Stuttering is a DSM-V psychiatric condition for which there are no FDA-approved medications for treatment. Medications with dopamine-blocking activity have shown the most efficacy; however, they can be limited by their respective side-effect profiles. Other agents have been tried with limited efficacy, but newer medications with novel mechanisms are showing promise in the pharmacologic treatment of stuttering.

 

Speech therapy can teach the one affected how to slow down speech and learn to notice when they stutter. The person may speak very slowly and deliberately when beginning speech therapy, but they can work up to a more natural speech pattern over time.

 

Some people who stutter use electronic devices to help control fluency.

Continued in the report…..

Stuttering Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of stuttering, diagnosed prevalent cases of stuttering and gender-specific diagnosed prevalent cases of stuttering scenario of stuttering in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Key Findings

  • Total prevalent cases of stuttering in the 7MM were found to be approximately 3,981,012 in 2021. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019–2032).
  • Among 7MM, the United States has the highest prevalent cases of stuttering with 1,636,434 cases in 2021. 
  • The total diagnosed prevalent cases of stuttering in the 7MM were observed to be 878,024 in 2021. These cases are expected to increase during the study period (2019–2032).
  • A total of 409,108 diagnosed prevalent cases of stuttering were recorded in the US in 2021, these cases are expected to rise at a CAGR of 0.8% for the study period (2019–2032).
  • Among the European countries, Germany had the highest diagnosed prevalent population of Stuttering with 88,573 cases, followed by the UK with 67,196 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population. 
  • In Japan, 132,528 diagnosed prevalent cases of stuttering were recorded in the year 2021. 
  • As per DelveInsight’s assessment, for stuttering, the gender-specific distribution of the disease suggests male predominance with 658,518 cases while females were at a lower count with 219,506 cases in the 7MM.

Country-Wise Stuttering Epidemiology 

The epidemiology segment also provides the stuttering epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

Stuttering Drug Chapters

The drug chapter segment of the stuttering report encloses the detailed analysis of stuttering marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the stuttering clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

 

Stuttering Emerging Drugs 

 

Ecopipam: Emalex Biosciences Inc.

Ecopipam (EBS-101) is an investigational first-in-class drug being evaluated in pediatric patients for the treatment of Tourette syndrome (TS) and childhood-onset fluency disorder (stuttering) in adults. Ecopipam selectively blocks the actions of the neurotransmitter dopamine at the D1 receptor. Emalex Biosciences Inc. is currently investigating therapies for TS in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults. 

Products detail in the report…

List of products to be continued in the report…

Stuttering Market Outlook

Stuttering is a speech disorder characterized by repetition of sounds, syllables, or words; prolongation of sounds; and interruptions in speech known as blocks. Stuttering affects people of all ages, most often in children between the ages of 2 and 6 as they are developing their language skills. Although there is currently no cure for stuttering, there are a variety of treatments available. The nature of the treatment will differ based upon a person’s age, communication goals, and other factors. It is crucial to work with a speech-language pathologist to determine the best treatment options.

 

For very young children, early treatment may prevent developmental stuttering from becoming a lifelong problem. Health professionals generally recommend that a child be evaluated if they have stuttered for 3–6 months, exhibit struggle behaviors associated with stuttering or have a family history of stuttering or related communication disorders. Some researchers recommend that a child be evaluated every 3 months to determine if stuttering is increasing or decreasing.

 

Drugs such as alprazolam (an antianxiety agent), citalopram (a selective serotonin reuptake inhibitor), and clomipramine (strongly serotonergic drug) have been reported to reduce stuttering in selective patients

 

There is no approved drug for the treatment of stuttering. Treatment often involves teaching parents about ways to support their child’s production of fluent speech. There are many treatments for stuttering, however, none of the available treatments is 100% effective. Traditional speech therapy reduces the frequency and severity of a stutter and teaches stutterers to use effective communications skills.

 

Key Findings

  • The market size of stuttering in seven major markets was USD 40 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 13.4 % for the study period (2019–2032)
  • The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of stuttering.
  • Upcoming therapy, Ecopipam has the potential to create a significant positive shift in the stuttering market size.
  • The United States accounts for the largest market size of Stuttering, in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

 

The United States Market Outlook

This section provides the total stuttering market size and market size by therapies in the United States.

 

EU-5 Market Outlook

The total stuttering market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook 

The total stuttering market size and market size by therapies in Japan are provided.

Stuttering Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the stuttering market or expected to get launched in the market during the study period 2019–2032. The analysis covers the stuttering market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Stuttering Development Activities 

The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics. 

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for stuttering emerging therapies. 

Reimbursement Scenario in Stuttering

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 

Competitive Intelligence Analysis 

We perform competitively and market Intelligence analysis of the stuttering market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of stuttering, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the stuttering epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for stuttering is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the stuttering market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Stuttering market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the stuttering market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence stuttering R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for stuttering. The launch of emerging therapies will significantly impact the stuttering market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Stuttering Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Stuttering Pipeline Analysis
  • Stuttering Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Stuttering Report Key Strengths

  • 11-Years Forecast
  • The 7MM Coverage 
  • Stuttering Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake

Stuttering Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the stuttering market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the stuttering total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest stuttering market size during the forecast period (2022–2032)?
  • At what CAGR, the stuttering market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the stuttering market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the stuttering market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of stuttering?
  • What is the historical stuttering patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of stuttering at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to stuttering?
  • Out of the above-mentioned countries, which country would have the highest population of stuttering during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of stuttering along with the approved therapy?
  • What are the current treatment guidelines for the treatment of stuttering in the US and Europe?
  • What are the stuttering marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of stuttering?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of stuttering?
  • What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Stuttering therapies? 
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for stuttering and their status?
  • What are the key designations that have been granted for the emerging therapies for stuttering?
  • What are the 7MM historical and forecasted market of stuttering?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving stuttering.
  • To understand the future market competition in the stuttering market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for stuttering in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the stuttering market.
  • To understand the future market competition in the stuttering market."

1. Key Insights

2. Report Introduction

3. Stuttering Market Overview at a Glance

3.1. Market Share (%) Distribution of Stuttering by Therapies in 2019

3.2. Market Share (%) Distribution of Stuttering by Therapies in 2032

4. Stuttering Market: Future Perspective

5. Executive Summary of Stuttering

6. Disease Background and Overview: Stuttering

6.1. Introduction of Stuttering

6.2. Types of Stuttering

6.3. Risk Factors of Stuttering

6.4. Signs and Symptoms of Stuttering

6.5. Etiology and Causes of Stuttering

6.6. Pathophysiology of Stuttering

6.7. Diagnosis of Stuttering

6.7.1. Diagnostic Guidelines

6.7.1.1. WHO ICF Framework

6.7.1.2. German Guidelines on Fluency Disorders Based on ICF Mode

6.8. Treatment and Management of Stuttering

6.8.1. Treatment Guidelines

6.8.1.1. ASHA Guidelines

6.8.1.2. German Guidelines on Fluency Disorders

6.8.1.3. Infant Stuttering Clinical Guidelines, Japan

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Methodology of Epidemiology

7.3. Assumptions and Rationale: 7MM

7.4. Total Prevalent Cases of Stuttering in the 7MM

7.5. Total Diagnosed Prevalent Cases of Stuttering in the 7MM

7.6. The United States

7.6.1. Prevalent Cases of Stuttering in the United States

7.6.2. Diagnosed Prevalent Cases of Stuttering in the United States

7.6.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in the United States

7.7. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)

7.7.1. Germany

7.7.1.1. Prevalent Cases of Stuttering in Germany

7.7.1.2. Diagnosed Prevalent Cases of Stuttering in Germany

7.7.1.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in Germany

7.7.2. France

7.7.2.1. Prevalent Cases of Stuttering in France

7.7.2.2. Diagnosed Prevalent Cases of Stuttering in France

7.7.2.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in France

7.7.3. Italy

7.7.3.1. Prevalent Cases of Stuttering in Italy

7.7.3.2. Diagnosed Prevalent Cases of Stuttering in Italy

7.7.3.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in Italy

7.7.4. Spain

7.7.4.1. Prevalent Cases of Stuttering in Spain

7.7.4.2. Diagnosed Prevalent Cases of Stuttering in Spain

7.7.4.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in Spain

7.7.5 UK (United Kingdom)

7.7.5.1. Prevalent Cases of Stuttering in UK

7.7.5.2. Diagnosed Prevalent Cases of Stuttering in UK

7.7.5.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in UK

7.8. Japan

7.8.1. Prevalent Cases of Stuttering in Japan

7.8.2. Diagnosed Prevalent Cases of Stuttering in Japan

7.8.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in Japan

8. Patient Journey

9. Emerging Drugs

9.1. Ecopipam: Emalex Biosciences Inc.

9.1.1. Product Description

9.1.2. Other Development Activities

9.1.3. Clinical Development

9.1.4. Clinical Trials Information

9.1.5. Safety and Efficacy

9.1.6. Product Profile

9.1.7. Analysts’ Views

10. Stuttering: Seven Major Market Analysis

10.1. Key Findings

10.2. Methodology of Stuttering Market

10.3. Market Outlook

10.4. Potential of Emerging Therapy

10.5. Key Market Assumptions

10.6. Attribute Analysis

10.7. Total 7MM Stuttering market analysis (2019–2032) 

10.8. Total 7MM Stuttering market analysis by therapies (2019–2032) 

10.9. Region-Wise Market size of Stuttering

10.9.1. United States

10.9.1.1. Total Market Size of Stuttering

10.9.1.2. Total Market Size of Stuttering by therapies

10.9.2. EU-5

10.9.2.1. Germany

10.9.2.1.1. Total Market Size of Stuttering

10.9.2.1.2. Total Market Size of Stuttering by therapies

10.9.2.2. France

10.9.2.2.1. Total Market Size of Stuttering

10.9.2.2.2. Total Market Size of Stuttering by therapies

10.9.2.3. Italy

10.9.2.3.1. Total Market Size of Stuttering

10.9.2.3.2. Total Market Size of Stuttering by therapies

10.9.2.4. Spain

10.9.2.4.1. Total Market Size of Stuttering

10.9.2.4.2. Total Market Size of Stuttering by therapies

10.9.2.5. United Kingdom

10.9.2.5.1. Total Market Size of Stuttering

10.9.2.5.2. Total Market Size of Stuttering by therapies

10.9.3. Japan

10.9.3.1. Total Market Size of Stuttering

10.9.3.2. Total Market Size of Stuttering by Therapies

11. KOL Views

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Unmet Needs

16. Reimbursement and Market Access

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of Stuttering, Market, and Epidemiology (2019–2032)

Table 2: Risk Factor Chart

Table 3: Symptoms of Stuttering and Distinction From Normal Speech Disfluencies

Table 4: Diagnostic Instruments for stuttering

Table 5: Total Prevalent Cases of Stuttering in the 7MM (2019–2032)

Table 6: Total Diagnosed Prevalent Cases of Stuttering in the 7MM (2019–2032)

Table 7: Prevalent Cases of Stuttering in the US (2019–2032)

Table 8: Diagnosed Prevalent Cases of Stuttering in the US (2019–2032)

Table 9: Gender-specific Diagnosed Prevalent Cases of Stuttering in the US (2019–2032)

Table 10: Prevalent Cases of Stuttering in Germany (2019–2032)

Table 11: Diagnosed Prevalent Cases of Stuttering in Germany (2019–2032)

Table 12: Gender-specific Diagnosed Prevalent Cases of Stuttering in Germany (2019–2032)

Table 13: Prevalent Cases of Stuttering in France (2019–2032)

Table 14: Diagnosed Prevalent Cases of Stuttering in France (2019–2032)

Table 15: Gender-specific Diagnosed Prevalent Cases of Stuttering in France (2019–2032)

Table 16: Prevalent Cases of Stuttering in Italy (2019–2032)

Table 17: Diagnosed Prevalent Cases of Stuttering in Italy (2019–2032)

Table 18: Gender-specific Diagnosed Prevalent Cases of Stuttering in Italy (2019–2032)

Table 19: Prevalent Cases of Stuttering in Spain (2019–2032)

Table 20: Diagnosed Prevalent Cases of Stuttering in Spain (2019–2032)

Table 21: Gender-specific Diagnosed Prevalent Cases of Stuttering in Spain (2019–2032)

Table 22: Prevalent Cases of Stuttering in the UK (2019–2032)

Table 23: Diagnosed Prevalent Cases of Stuttering in the UK (2019–2032)

Table 24: Gender-specific Diagnosed Prevalent Cases of Stuttering in the UK (2019–2032)

Table 25: Prevalent Cases of Stuttering in Japan (2019–2032)

Table 26: Diagnosed Prevalent Cases of Stuttering in Japan (2019–2032)

Table 27: Gender-specific Diagnosed Prevalent Cases of Stuttering in Japan (2019–2032)

Table 28: Ecopipam, Clinical Trial Description, 2022

Table 29: Key Market Forecast Assumptions for Ecopipam (EBS-101)

Table 30: Market Size of Stuttering in the 7MM in USD Million (2019–2032)

Table 31: Market Size of Stuttering by Therapies in the 7MM in USD Million (2019–2032)

Table 32: Market Size of Stuttering in the US, in USD Million (2019–2032)

Table 33: Market Size of Stuttering by Therapies in the US in USD Million (2019–2032)

Table 34: Market Size of Stuttering in the EU-5, in USD Million (2019–2032)

Table 35: Market Size of Stuttering by Therapies in Germany, in USD Million (2019–2032)

Table 36: Market Size of Stuttering by Therapies in France, in USD Million (2019–2032)

Table 37: Market Size of Stuttering by Therapies in Italy, in USD Million (2019–2032)

Table 38: Market Size of Stuttering by Therapies in Spain, in USD Million (2019–2032)

Table 39: Market Size of Stuttering by Therapies in the UK, in USD Million (2019–2032)

Table 40: Market Size of Stuttering by Therapies in the EU-5, in USD Million (2019–2032)

Table 41: Market Size of Stuttering in Japan, in USD Million (2019–2032)

Table 42: Market Size of Stuttering by Therapies in Japan in USD Million (2019–2032)

List of Figures

Figure 1: Subtypes of Fluency Disorders

Figure 2: Types of Stutter

Figure 3: Primary Behaviors of Stuttering

Figure 4: Etiology of Stuttering

Figure 5: Causes of Stuttering

Figure 6: Total Prevalent Cases of Stuttering in the 7MM (2019–2032)

Figure 7: Total Diagnosed Prevalent Cases of Stuttering in the 7MM (2019–2032)

Figure 8: Prevalent Cases of Stuttering in the US (2019–2032)

Figure 9: Diagnosed Prevalent Cases of Stuttering in the US (2019–2032)

Figure 10: Gender-specific Diagnosed Prevalent Cases of Stuttering in the US (2019–2032)

Figure 11: Prevalent Cases of Stuttering in Germany (2019–2032)

Figure 12: Diagnosed Prevalent Cases of Stuttering in Germany (2019–2032)

Figure 13: Gender-specific Diagnosed Prevalent Cases of Stuttering in Germany (2019–2032)

Figure 14: Prevalent Cases of Stuttering in France (2019–2032)

Figure 15: Diagnosed Prevalent Cases of Stuttering in France (2019–2032)

Figure 16: Gender-specific Diagnosed Prevalent Cases of Stuttering in France (2019–2032)

Figure 17: Prevalent Cases of Stuttering in Italy (2019–2032)

Figure 18: Diagnosed Prevalent Cases of Stuttering in Italy (2019–2032)

Figure 19: Gender-specific Diagnosed Prevalent Cases of Stuttering in Italy (2019–2032)

Figure 20: Prevalent Cases of Stuttering in Spain (2019–2032)

Figure 21: Diagnosed Prevalent Cases of Stuttering in Spain (2019–2032)

Figure 22: Gender-specific Diagnosed Prevalent Cases of Stuttering in Spain (2019–2032)

Figure 23: Prevalent Cases of Stuttering in the UK (2019–2032)

Figure 24: Diagnosed Prevalent Cases of Stuttering in the UK (2019–2032)

Figure 25: Gender-specific Diagnosed Prevalent Cases of Stuttering in the UK (2019–2032)

Figure 26: Prevalent Cases of Stuttering in Japan (2019–2032)

Figure 27: Diagnosed Prevalent Cases of Stuttering in Japan (2019–2032)

Figure 28: Gender-specific Diagnosed Prevalent Cases of Stuttering in Japan (2019–2032)

Figure 29: Patient Journey

Figure 30: Market Size of Stuttering in the 7MM in USD Million (2019–2032)

Figure 31: Market Size of Stuttering by Therapies in the 7MM in USD Million (2019–2032)

Figure 32: Market Size of Stuttering in the United States, USD Millions (2019–2032)

Figure 33: Market Size of Stuttering by Therapies in the US, in USD Million (2019–2032)

Figure 34: Market Size of Stuttering in the EU5, USD Millions (2019–2032)

Figure 35: Market Size of Stuttering by Therapies in the EU5, in USD Million (2019–2032)

Figure 36: Market Size of Stuttering in Japan, USD Millions (2019–2032)

Figure 37: Market Size of Stuttering by Therapies in Japan, in USD Million (2019–2032)

Figure 38: Market Drivers

Figure 39: Market Barriers

Figure 40: SWOT Analysis

Figure 41: Unmet Needs

Emalex Biosciences Inc.

 

Forward to Friend

Need A Quote